$0.27
+0.00 (+0.49%)
Open$0.27
Previous Close$0.27
Day High$0.27
Day Low$0.26
52W High$5.14
52W Low$0.20
Volume—
Avg Volume13.39M
Market Cap12.59M
P/E Ratio—
EPS$-1.85
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+18,386.5% upside
Current
$0.27
$0.27
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.45M | 848.4K | 9.03M |
| Net Income | -79,872,364 | -80,993,442 | 1.99M |
| Profit Margin | -5,491.3% | -10,050.9% | 22.0% |
| EBITDA | -82,438,334 | -92,813,868 | 3.04M |
| Free Cash Flow | — | — | 1.40M |
| Rev Growth | — | -24.1% | +1.4% |
| Debt/Equity | 0.00 | — | 0.61 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |